Systemic delivery of E6/7 siRNA using novel lipidic particles and its application with cisplatin in cervical cancer mouse models

Gene Therapy

Volumn 18, Issue 1, 2011, Pages 14-22

  Wu, S Y ^a   Singhania, A ^a   Burgess, M ^a   Putral, L N ^a   Kirkpatrick, C ^a   Davies, N M ^a   McMillan, N A J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

cancer; chemotherapy; liposome; RNA interference; siRNA delivery

Indexed keywords

CISPLATIN; LIPID; PROTEIN E6; PROTEIN E7; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DELIVERY; DRUG FORMULATION; EXTRACELLULAR MATRIX; FEMALE; FREEZE DRYING; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HYDRATION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; CERVIX UTERI; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; GENE SILENCING; LIPIDS; MICE; MICE, INBRED C57BL; NEOPLASMS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; TRANSFECTION; UTERINE CERVICAL NEOPLASMS;

EID: 78650997059     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.113     Document Type: Article

References (46)

1. Putral LN, Bywater MJ, Gu W, Saunders NA, Gabrielli BG, Leggatt GR, et al. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol Pharmacol 2005; 68: 1311-1319.
2. Putral L, Gu W, McMillan N. RNA interference for the treatment of cancer. Drug News Perspect 2006; 19: 317-324.
3. Wang W, Wang CY, Dong JH, Chen X, Zhang M, Zhao G. Identification of effective siRNA against K-ras in human pancreatic cancer cell line MiaPaCa-2 by siRNA expression cassette. World J Gastroenterol 2005; 11: 2026-2031.
4. Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A, et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009; 119: 661-673.
5. Li SD, Chen YC, Hackett MJ, Huang L. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther 2008; 16: 163-169.
6. Yagi N, Manabe I, Tottori T, Ishihara A, Ogata F, Kim JH, et al. A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo. Cancer Res 2009; 69: 6531-6538.
7. Wu SY, Putral LN, Liang M, Chang HI, Davies NM, McMillan NA. Development of a novel method for formulating stable siRNA-loaded lipid particles for in vivo use. Pharm Res 2009; 26: 512-522.
8. Wright TC, Van Damme P, Schmitt H-J, Meheus A. Chapter 14: HPV vaccine introduction in industrialized countries. Vaccine 2006; 24: S122-S131.
9. Moore DH. Chemotherapy for advanced, recurrent, and metastatic cervical cancer. J Natl Compr Canc Netw 2008; 6: 53-57.
10. Jiang M, Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 2002; 21: 6041-6048.
11. Hall AHS, Alexander KA. RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J Virol 2003; 77: 6066-6069.
12. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003; 22: 5938-5945.
13. Lea JS, Sunaga N, Sato M, Kalahasti G, Miller DS, Minna JD, et al. Silencing of HPV 18 oncoproteins with RNA interference causes growth inhibition of cervical cancer cells. Reprod Sci 2007; 14: 20-28.
14. Fujii T, Saito M, Iwasaki E, Ochiya T, Takei Y, Hayashi S, et al. Intratumor injection of small interfering RNA-targeting human papillomavirus 18 E6 and E7 successfully inhibits the growth of cervical cancer. Int J Oncol 2006; 29: 541-548.
15. Niu X, Peng Z, Duan W, Wang H, Wang P. Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. Int J Gynecol Cancer 2006; 16: 743-751.
16. Viel T, Boisgard R, Kuhnast B, Jego B, Siquier-Pernet K, Hinnen F, et al. Molecular imaging study on in vivo distribution and pharmacokinetics of modified small interfering RNAs (siRNAs). Oligonucleotides 2008; 18: 201-212.
17. Jonson AL, Rogers LM, Ramakrishnan S, Downs Jr LS. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer. Gynecol Oncol 2008; 111: 356-364.
18. Yamato K, Yamada T, Kizaki M, Ui-Tei K, Natori Y, Fujino M, et al. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer. Cancer Gene Ther 2008; 15: 140-153.
19. Ji H, Chang EY, Lin KY, Kurman RJ, Pardoll DM, Wu TC. Antigen-specific immuno-therapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer 1998; 78: 41-45.
20. Garbuzenko OB, Saad M, Betigeri S, Zhang M, Vetcher AA, Soldatenkov VA, et al. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleo-tides and anticancer drug. Pharm Res 2009; 26: 382-394.
21. Koivusalo R, Krausz E, Helenius H, Hietanen S. Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs. Mol Pharmacol 2005; 68: 372-382.
22. Liu ZG, Zhao LN, Liu YW, Li TT, Fan DM, Chen JJ. Activation of Cdc2 contributes to apoptosis in HPV E6 expressing human keratinocytes in response to therapeutic agents. J Mol Biol 2007; 374: 334-345.
23. Sato A, Takagi M, Shimamoto A, Kawakami S, Hashida M. Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials 2007; 28: 1434-1442.
24. Abrams MT, Koser ML, Seitzer J, Williams SC, Dipietro MA, Wang W, et al. Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol Ther 2009; 18: 171-180.
25. Sorensen D, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003; 327: 761-766.
26. Yano J, Hirabayashi K, Nakagawa S, Yamaguchi T, Nogawa M, Kashimori I, et al. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res 2004; 10: 7721-7726.
27. Chien P, Wang J, Carbonaro D, Lei S, Miller B, Sheikh S, et al. Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther 2005; 12: 321-328.
28. Pal A, Ahmad A, Khan S, Sakabe I, Zhang CB, Kasid UN, et al. Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int J Oncol 2005; 26: 1087-1091.
29. Merkel OM, Librizzi D, Pfestroff A, Schurrat T, Buyens K, Sanders NN, et al. Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging. J Control Release 2009; 138: 148-159.
30. Santel A, Aleku M, Keil O, Endruschat J, Esche V, Durieux B, et al. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther 2006; 13: 1360-1370.
31. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 2007; 104: 15549-15554.
32. Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, et al. Ta rg e ting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res 2008; 68: 9078-9086.
33. Medarova Z, Pham W, Farrar C, Petkova V, Moore A. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med 2007; 13: 372-377.
34. Crombez L, Morris MC, Dufort S, Aldrian-Herrada G, Nguyen Q, Mc Master G, et al. Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res 2009; 37: 4559-4569.
35. Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G, et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 2006; 13: 1222-1234.
36. Sonoke S, Ueda T, Fujiwara K, Sato Y, Takagaki K, Hirabayashi K, et al. Tu m o r r e g r e s s i o n in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes. Cancer Res 2008; 68: 8843-8851.
37. Liu WL, Green N, Seymour LW, Stevenson M. Paclitaxel combined with siRNA targeting HPV16 oncogenes improves cytotoxicity for cervical carcinoma. Cancer Gene Ther 2009; 16: 764-775.
38. Bonner J, Harari P, Giralt J, Azarnia N, Cohen R, Raben D, et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol 2004; 22: 5507 (Meeting Abstracts).
39. Hagemann T, Bozanovic T, Hooper S, Ljubic A, Slettenaar VI, Wilson JL, et al. Molecular profiling of cervical cancer progression. Br J Cancer 2007; 96: 321-328.
40. Manavi M, Hudelist G, Fink-Retter A, Gschwandtler-Kaulich D, Pischinger K, Czerwenka K. Gene profiling in Pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma. Gynecol Oncol 2007; 105: 418-426.
41. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 21-26.
42. Gu W, Putral L, Hengst K, Minto K, Saunders NA, Leggatt G, et al. Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Ther 2006; 13: 1023-1032.
43. Lee CH, Ni YH, Chen CC, Chou CK, Chang FH. Synergistic effect of polyethylenimine and cationic liposomes in nucleic acid delivery to human cancer cells. Biochim Biophys Acta 2003; 1611: 55-62.
44. Sakurai F, Nishioka T, Saito H, Baba T, Okuda A, Matsumoto O, et al. Interaction between DNA-cationic liposome complexes and erythrocytes is an important factor in systemic gene transfer via the intravenous route in mice: the role of the neutral helper lipid. Gene Ther 2001; 8: 677-686.
45. Ito Y, Kawakami S, Charoensit P, Higuchi Y, Hashida M. Evaluation of proinflammatory cytokine production and liver injury induced by plasmid DNA/cationic liposome complexes with various mixing ratios in mice. Eur J Pharm Biopharm 2009; 71: 303-309.
46. Charoensit P, Kawakami S, Higuchi Y, Hashida M. Incorporation of all-trans retinoic acid into lipoplexes inhibits nuclear factor kappaB activation mediated liver injury induced by lipoplexes in mice. J Gene Med 2008; 10: 61-69.